针对慢性心力衰竭患者的威利吉全球研究：VICTOR 试验的设计

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure Pub Date : 2024-10-30 DOI:10.1002/ejhf.3501

Yogesh N.V. Reddy, Javed Butler, Kevin J. Anstrom, Robert O. Blaustein, Marc P. Bonaca, Stefano Corda, Justin A. Ezekowitz, Carolyn S.P. Lam, Eldrin F. Lewis, JoAnn Lindenfeld, Ciaran J. McMullan, Robert J. Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Giuseppe M.C. Rosano, Clara I. Saldarriaga, Michele Senni, James Udelson, Adriaan A. Voors, Faiez Zannad

{"title":"针对慢性心力衰竭患者的威利吉全球研究：VICTOR 试验的设计","authors":"Yogesh N.V. Reddy, Javed Butler, Kevin J. Anstrom, Robert O. Blaustein, Marc P. Bonaca, Stefano Corda, Justin A. Ezekowitz, Carolyn S.P. Lam, Eldrin F. Lewis, JoAnn Lindenfeld, Ciaran J. McMullan, Robert J. Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Giuseppe M.C. Rosano, Clara I. Saldarriaga, Michele Senni, James Udelson, Adriaan A. Voors, Faiez Zannad","doi":"10.1002/ejhf.3501","DOIUrl":null,"url":null,"abstract":"In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, the soluble guanylate cyclase stimulator vericiguat reduced the risk of hospitalization for heart failure (HHF) or cardiovascular death in patients with heart failure (HF) and reduced ejection fraction (HFrEF) with recent worsening HF. The effect of vericiguat in patients with HFrEF without recent worsening HF remains unknown. The VICTOR (Vericiguat Global Study in Participants with Chronic Heart Failure) trial was designed to assess the efficacy and safety of vericiguat in patients with ejection fraction ≤40% without recent worsening HF on a background of current foundational HFrEF therapy.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"130 1","pages":""},"PeriodicalIF":16.9000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial\",\"authors\":\"Yogesh N.V. Reddy, Javed Butler, Kevin J. Anstrom, Robert O. Blaustein, Marc P. Bonaca, Stefano Corda, Justin A. Ezekowitz, Carolyn S.P. Lam, Eldrin F. Lewis, JoAnn Lindenfeld, Ciaran J. McMullan, Robert J. Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Giuseppe M.C. Rosano, Clara I. Saldarriaga, Michele Senni, James Udelson, Adriaan A. Voors, Faiez Zannad\",\"doi\":\"10.1002/ejhf.3501\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, the soluble guanylate cyclase stimulator vericiguat reduced the risk of hospitalization for heart failure (HHF) or cardiovascular death in patients with heart failure (HF) and reduced ejection fraction (HFrEF) with recent worsening HF. The effect of vericiguat in patients with HFrEF without recent worsening HF remains unknown. The VICTOR (Vericiguat Global Study in Participants with Chronic Heart Failure) trial was designed to assess the efficacy and safety of vericiguat in patients with ejection fraction ≤40% without recent worsening HF on a background of current foundational HFrEF therapy.\",\"PeriodicalId\":164,\"journal\":{\"name\":\"European Journal of Heart Failure\",\"volume\":\"130 1\",\"pages\":\"\"},\"PeriodicalIF\":16.9000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ejhf.3501\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ejhf.3501","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

在 VICTORIA（射血分数降低型心力衰竭患者维力古阿特全球研究）试验中，可溶性鸟苷酸环化酶刺激剂维力古阿特降低了因心力衰竭（HHF）住院或心血管死亡的风险，这些患者均为射血分数降低型心力衰竭（HFrEF）且近期心力衰竭病情恶化的患者。韦立克对近期未出现恶化的 HFrEF 患者的效果尚不清楚。VICTOR（慢性心力衰竭患者维力古阿特全球研究）试验旨在评估维力古阿特在射血分数≤40%且近期无恶化的心力衰竭患者中的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial

查看原文本刊更多论文

Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial

In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, the soluble guanylate cyclase stimulator vericiguat reduced the risk of hospitalization for heart failure (HHF) or cardiovascular death in patients with heart failure (HF) and reduced ejection fraction (HFrEF) with recent worsening HF. The effect of vericiguat in patients with HFrEF without recent worsening HF remains unknown. The VICTOR (Vericiguat Global Study in Participants with Chronic Heart Failure) trial was designed to assess the efficacy and safety of vericiguat in patients with ejection fraction ≤40% without recent worsening HF on a background of current foundational HFrEF therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Heart Failure 医学-心血管系统

CiteScore

27.30

自引率

11.50%

发文量

365

审稿时长

1 months

期刊介绍： European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.